

Julie R Gralow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9018543/publications.pdf>

Version: 2024-02-01

78
papers

6,004
citations

136940

32
h-index

76898

74
g-index

79
all docs

79
docs citations

79
times ranked

7533
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 32-42. | 2.4 | 4 |
| 2 | Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. <i>JCO Oncology Practice</i> , 2022, 18, e426-e441. | 2.9 | 16 |
| 3 | A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptorâ€“positive Breast Cancer, SWOG S1222. <i>Clinical Cancer Research</i> , 2022, 28, 611-617. | 7.0 | 4 |
| 4 | Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 438-448. | 1.6 | 35 |
| 5 | Cancer research collaboration between the UK and the USA: reflections on the 2021 G20 Summit announcement. <i>Lancet Oncology</i> , The, 2022, 23, 460-462. | 10.7 | 5 |
| 6 | Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2022, 40, 2163-2171. | 1.6 | 68 |
| 7 | Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trialsâ€“Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop. <i>JCO Global Oncology</i> , 2022, , . | 1.8 | 2 |
| 8 | Breakthrough COVID-19 cases and hospitalization risk: ASCO COVID-19 registry.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18807-e18807. | 1.6 | 0 |
| 9 | Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 54-63. | 6.3 | 98 |
| 10 | ¹⁸ F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2â€“ Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 184-190. | 5.0 | 20 |
| 11 | Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). <i>Supportive Care in Cancer</i> , 2021, 29, 2509-2517. | 2.2 | 17 |
| 12 | The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155. | 6.3 | 13 |
| 13 | When cardiomyopathy, cancer, and COVIDâ€“19 collide: A case report. <i>Breast Journal</i> , 2021, 27, 384-386. | 1.0 | 0 |
| 14 | Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2021, 113, 989-996. | 6.3 | 13 |
| 15 | Advancing Breast Cancer Advocacy in Eastern Europe and Central Asia: Findings From Womenâ€™s Empowerment Cancer Advocacy Network (WE CAN) Summits. <i>JCO Global Oncology</i> , 2021, 7, 585-592. | 1.8 | 2 |
| 16 | Time to Focus on Breast Cancer in Young Adults. <i>JCO Oncology Practice</i> , 2021, 17, 314-316. | 2.9 | 1 |
| 17 | Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958. | 1.6 | 40 |
| 18 | Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6115-6123. | 7.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347. | 27.0 | 363 |
| 20 | Couple Communication in Cancer: Protocol for a Multi-Method Examination. <i>Frontiers in Psychology</i> , 2021, 12, 769407. | 2.1 | 9 |
| 21 | Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020, 112, 698-707. | 6.3 | 48 |
| 22 | Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505. | 7.1 | 51 |
| 23 | Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). <i>Journal of Clinical Oncology</i> , 2020, 38, 804-814. | 1.6 | 142 |
| 24 | Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. <i>Journal of Clinical Oncology</i> , 2020, 38, 2122-2129. | 1.6 | 59 |
| 25 | Breast cancer patient advocacy: A qualitative study of the challenges and opportunities for civil society organizations in low-income and middle-income countries. <i>Cancer</i> , 2020, 126, 2439-2447. | 4.1 | 6 |
| 26 | Resource-Stratified Guideline-Based Cancer Care Should Be a Priority: Historical Context and Examples of Success. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 217-226. | 3.8 | 3 |
| 27 | The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource-Stratified Phased Implementation: Methods and overview. <i>Cancer</i> , 2020, 126, 2339-2352. | 4.1 | 54 |
| 28 | The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 6. | 5.2 | 26 |
| 29 | Patient Advocacy Approaches to Improving Care for Breast and Cervical Cancer in East and Southern Africa. <i>JCO Global Oncology</i> , 2020, 6, 49-55. | 1.8 | 4 |
| 30 | Breast cancer treatment: A phased approach to implementation. <i>Cancer</i> , 2020, 126, 2365-2378. | 4.1 | 74 |
| 31 | Recommendations from the ASCO Academic Global Oncology Task Force. <i>JCO Global Oncology</i> , 2020, 6, 1666-1673. | 1.8 | 8 |
| 32 | Evaluating the Effect of a Video Education Curriculum for First Time Breast Cancer Patients: a Prospective RCT Feasibility Study. <i>Journal of Cancer Education</i> , 2019, 34, 1234-1240. | 1.3 | 9 |
| 33 | Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1226-1234. | 27.0 | 95 |
| 34 | Role of Family Obligation Stress on Ugandan Women's Participation in Preventive Breast Health. <i>Oncologist</i> , 2019, 24, 624-631. | 3.7 | 9 |
| 35 | Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. <i>Clinical Breast Cancer</i> , 2019, 19, e283-e296. | 2.4 | 24 |
| 36 | Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). <i>Breast</i> , 2018, 39, 131-138. | 2.2 | 167 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e143-e149. | 2.4 | 15 |
| 38 | ASCO Resource-Stratified Guidelines: Methods and Opportunities. <i>Journal of Global Oncology</i> , 2018, 4, 1-8. | 0.5 | 7 |
| 39 | Breast Cancer Beliefs as Potential Targets for Breast Cancer Awareness Efforts to Decrease Late-Stage Presentation in Uganda. <i>Journal of Global Oncology</i> , 2018, 4, 1-9. | 0.5 | 10 |
| 40 | Links Between Communication and Relationship Satisfaction Among Patients With Cancer and Their Spouses: Results of a Fourteen-Day Smartphone-Based Ecological Momentary Assessment Study. <i>Frontiers in Psychology</i> , 2018, 9, 1843. | 2.1 | 36 |
| 41 | Prospective Study of Serial ¹⁸ F-FDG PET and ¹⁸ F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1823-1830. | 5.0 | 41 |
| 42 | Resource-stratified implementation of a community-based breast cancer management programme in Peru. <i>Lancet Oncology</i> , The, 2017, 18, e607-e617. | 10.7 | 25 |
| 43 | Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance) Tj ETQq1, 1 0.784314 rgBT C | 2.3 | 18 |
| 44 | Hot flashes in breast cancer survivors: Frequency, severity and impact. <i>Breast</i> , 2016, 27, 116-121. | 2.2 | 45 |
| 45 | Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219. | 27.0 | 507 |
| 46 | Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. <i>Journal of Clinical Oncology</i> , 2016, 34, 699-705. | 1.6 | 42 |
| 47 | Screening MRI in Women With a Personal History of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv349. | 6.3 | 118 |
| 48 | Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. <i>Journal of Clinical Oncology</i> , 2015, 33, 1910-1917. | 1.6 | 83 |
| 49 | Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-708. | 1.6 | 171 |
| 50 | Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. <i>BMC Cancer</i> , 2015, 15, 535. | 2.6 | 11 |
| 51 | SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 58-64. | 1.6 | 89 |
| 52 | Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. <i>Journal of Clinical Oncology</i> , 2015, 33, 503-503. | 1.6 | 16 |
| 53 | Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014, 32, 3744-3752. | 1.6 | 771 |
| 54 | Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329. | 1.6 | 210 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014, 32, 3483-3489. | 1.6 | 543 |
| 56 | SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.. <i>Journal of Clinical Oncology</i> , 2014, 32, 558-558. | 1.6 | 12 |
| 57 | Supplement use during an intergroup clinical trial for breast cancer (S0221). <i>Breast Cancer Research and Treatment</i> , 2013, 137, 903-913. | 2.5 | 31 |
| 58 | The importance of survivors and partners in improving breast cancer outcomes in Uganda. <i>Breast</i> , 2013, 22, 138-141. | 2.2 | 21 |
| 59 | Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast) <i>Tj ETQq1 1 0.784314 rgBT /Over to Oncology, The</i> , 2012, 13, 734-742. | 10.7 | 168 |
| 60 | Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 435-444. | 27.0 | 352 |
| 61 | Can bone-targeted therapy reduce recurrence and improve survival in early-stage breast cancer?. <i>Oncology</i> , 2012, 26, 969-70. | 0.5 | 1 |
| 62 | Bone Disease in Breast Cancer: The Era of New Targeted Therapies. <i>Current Breast Cancer Reports</i> , 2010, 2, 25-31. | 1.0 | 0 |
| 63 | Breast cancer advocacy: changing perceptions. <i>Salud Publica De Mexico</i> , 2009, 51, s323-s328. | 0.4 | 10 |
| 64 | Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable. <i>Clinical Breast Cancer</i> , 2008, 8, 33-37. | 2.4 | 14 |
| 65 | Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screeningâ€™ A Report From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2008, 26, 313-325. | 1.6 | 79 |
| 66 | Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease. <i>Journal of Clinical Oncology</i> , 2008, 26, 814-819. | 1.6 | 352 |
| 67 | Managing Metastatic Bone Pain: The Role of Bisphosphonates. <i>Journal of Pain and Symptom Management</i> , 2007, 33, 462-472. | 1.2 | 96 |
| 68 | Breast cancer 2004: Progress and promise on the clinical front. <i>Physica Medica</i> , 2006, 21, 2. | 0.7 | 8 |
| 69 | Optimizing the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, S9-S15. | 2.5 | 64 |
| 70 | Evolving Role of Bisphosphonates in Women Undergoing Treatment for Localized and Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 5, S54-S62. | 2.4 | 12 |
| 71 | University of Washington High-Dose Cyclophosphamide, Mitoxantrone, and Etoposide Experience in Metastatic Breast Cancer: Unexpected Cardiac Toxicity. <i>Journal of Clinical Oncology</i> , 2001, 19, 3903-3904. | 1.6 | 3 |
| 72 | The role of bisphosphonates as adjuvant therapy for breast cancer. <i>Current Oncology Reports</i> , 2001, 3, 506-515. | 4.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. <i>Cancer</i> , 2001, 92, 720-729. | 4.1 | 234 |
| 74 | Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. <i>Cancer</i> , 1999, 85, 2410-2423. | 4.1 | 107 |
| 75 | Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. , 1999, 85, 2410. | | 1 |
| 76 | Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. <i>Cancer</i> , 1999, 85, 2410-2423. | 4.1 | 6 |
| 77 | Immunity to Oncogenic Proteins. <i>Immunological Reviews</i> , 1995, 145, 33-59. | 6.0 | 167 |
| 78 | Immunity to the <i>HER2/neu</i> Oncogenic Protein. <i>Novartis Foundation Symposium</i> , 1994, 187, 198-211. | 1.1 | 7 |